Do this Before Elon’s Reveal on January 22nd

Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.

Charles Silberstein net worth and biography

Charles Silberstein Biography and Net Worth

CFO of Applied Therapeutics

Dr. Charles (Chuck) Silberstein, M.D., MBA, CFA, joined Applied Therapeutics as Chief Financial Officer and Head of Business Development in May 2020. Dr. Silberstein formerly served as Senior Vice President of Corporate Business Development at Allergan plc (acquired by AbbVie). Along with broad corporate strategy and business development skills, Dr. Silberstein brings more than 20 years of investment and capital markets experience to Applied Therapeutics, as a portfolio manager at The Boston Company Asset Management and Goldman Sachs Asset Management and as a senior healthcare equity analyst at JP Morgan Asset Management. Dr. Silberstein received his M.D. from Albert Einstein College of Medicine and his MBA from Columbia Business School.

What is Charles Silberstein's net worth?: The estimated net worth of Charles Silberstein is at least $88,242.02 as of June 8th, 2021. Dr. Silberstein owns 87,803 shares of Applied Therapeutics stock worth more than $88,242 as of December 18th. This net worth estimate does not reflect any other assets that Dr. Silberstein may own. Learn More about Charles Silberstein's net worth.
How do I contact Charles Silberstein?: The corporate mailing address for Dr. Silberstein and other Applied Therapeutics executives is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. Applied Therapeutics can also be reached via phone at (212) 220-9226 and via email at [email protected]. Learn More on Charles Silberstein's contact information.
Has Charles Silberstein been buying or selling shares of Applied Therapeutics?: Charles Silberstein has not been actively trading shares of Applied Therapeutics during the past quarter. Most recently, Charles Silberstein sold 5,047 shares of the business's stock in a transaction on Tuesday, June 8th. The shares were sold at an average price of $21.42, for a transaction totalling $108,106.74. Following the completion of the sale, the chief financial officer now directly owns 87,803 shares of the company's stock, valued at $1,880,740.26. Learn More on Charles Silberstein's trading history.
Who are Applied Therapeutics' active insiders?: Applied Therapeutics' insider roster includes Riccardo Perfetti (Insider), Shoshana Shendelman (CEO), and Charles Silberstein (CFO). Learn More on Applied Therapeutics' active insiders.
Are insiders buying or selling shares of Applied Therapeutics?: During the last twelve months, insiders at the sold shares 9 times. They sold a total of 1,128,473 shares worth more than $6,039,216.15. The most recent insider tranaction occured on August, 14th when CEO Shoshana Shendelman sold 119,591 shares worth more than $709,174.63. Insiders at Applied Therapeutics own 8.6% of the company. Learn More about insider trades at Applied Therapeutics.
Information on this page was last updated on 8/14/2024.

Charles Silberstein Insider Trading History at Applied Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/8/2021	Sell	5,047	$21.42	$108,106.74	87,803

Charles Silberstein Buying and Selling Activity at Applied Therapeutics

Applied Therapeutics Company Overview

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Today's Range

Now: $1.01

$0.95

$1.06

50 Day Range

MA: $7.07

$1.10

$10.24

2 Week Range

Now: $1.01

$0.95

$10.62

Volume

3,396,297 shs

Average Volume

2,584,863 shs

Market Capitalization

$116.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76

Do this Before Elon’s Reveal on January 22nd

From Brownstone Research | Ad

I urge you to watch this video now.